BGMS

#4899
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.86
0.86
Jahresspanne
0.57
6.70
Tagesänderung
-3.37%
Monatliche Änderung
-1.15%
6 month change
-10.06%
Jahresänderung
-85.67%
Vorheriger Schlusskurs
0.8 9
Open
0.8 6
Tief
0.8 6
Hoch
0.8 6
Volumen
3
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q1 FY2012

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on March 6, 2012. The filing addresses a material modification to the rights of security holders regarding the company's 6% Convertible Exchangeable Preferred Stock.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on dividend declarations and board composition changes.

Material Changes Versus Prior Period

  • Dividend Omission: The Board of Directors decided not to declare the quarterly cash dividend for the first quarter of 2012, which was originally scheduled to be payable on May 1, 2012.
  • Accumulated Arrears: This omission adds to a history of unpaid dividends, including all four quarters of fiscal year 2009, the first three quarters of fiscal year 2010, and the last three quarters of fiscal year 2011.
  • Board Expansion: Due to the failure to pay an aggregate of at least six quarterly dividends, the Board size was increased by two members. Holders of the Preferred Stock elected two directors on May 24, 2011, to fill these vacancies.

Guidance, Outlook, and Risks

The filing does not contain financial guidance or management commentary on future operations. The primary contingency noted is that the directorships held by the two Preferred Stock-elected directors will terminate only when the Company pays all accrued but unpaid dividends. The failure to pay dividends continues to accrue.

Key Facts for Investor Verification

  • Verify the total amount of accrued but unpaid dividends on the 6% Convertible Exchangeable Preferred Stock.
  • Confirm the current composition of the Board of Directors, specifically the two directors elected by Preferred Stock holders.
  • Review the company's cash position to assess the likelihood of paying the accrued dividends to restore the original Board size.
  • Check for any subsequent filings regarding the payment of the Q1 2012 dividend or further defaults.